No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Shares in Alliance Pharma slipped on Friday after the healthcare company said that its full-year results would be delayed.
Alliance, which had been due to publish its preliminary results for 2023 on 9 April, said figures are now expected to be released on 23 April.
"The group's auditor has determined that the volume of work required to complete the audit has exceeded its original expectations, necessitating a short delay in the reporting timetable," the statement said.
Nevertheless, the company assured that details provided in its latest trading update in January "remain accurate".
Alliance has already reported revenues of £182.7m for 2023, up 6% on the previous year, while underlying profits were said to be in line with market expectations.
The stock was down 2% at 37.66p by 0803 BST.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.